Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2005

01-10-2005

Changes in Indication and Results After Resection of Hepatic Metastases From Noncolorectal Primary Tumors: A Single-Institutional Review

Authors: Süleyman Yedibela, MD, Jonas Gohl, MD, Valentina Graz, MD, Mona Kathrin Pfaffenberger, MD, Susanne Merkel, MD, Werner Hohenberger, MD, and Thomas Meyer, PhD

Published in: Annals of Surgical Oncology | Issue 10/2005

Login to get access

Abstract

Background

The isolated occurrence of noncolorectal liver metastases is rare. The available data are inconsistent in terms of indication for surgery, treatment, and outcome, so a generally applicable therapeutic algorithm is currently lacking.

Methods

A total of 162 patients underwent resection for noncolorectal liver metastases between 1978 and 2001. The patients were divided into two groups from different time periods (group 1, 1978–1989; group 2, 1990–2001) that were similar in terms of number of patients, operating surgeons, and surgical techniques used. The groups were compared, and the data were retrospectively analyzed with regard to indication, survival, and factors predictive for survival.

Results

Resection was performed to remove liver metastases from noncolorectal gastrointestinal carcinoma (n = 50), neuroendocrine tumors (n = 12), genitourinary primary tumors (n = 11), breast carcinoma (n = 24), leiomyosarcoma (n = 15), and metastases from other primary cancers (n = 50). Extrahepatic tumor involvement was seen in 38 (23%) of the 162 cases. Sixty-two (38%) major hepatectomies and 100 (62%) minor resections were performed. In 100 (62%) of 162 patients, a curative resection (R0) could be achieved. Overall 2- and 5-year survival rates of 49% and 26%, respectively, were observed, and the median survival was 23 months. Survival was significantly longer in patients who underwent an R0 resection.

Conclusions

In selected patients, resection of noncolorectal liver metastases is associated with a 5-year survival rate of up to 50%. Resection of liver metastases from gastrointestinal adenocarcinomas correlates with a poor prognosis. Extrahepatic metastases may be considered a relative contraindication for liver resection.
Literature
1.
Berney T, Mentha G, Roth AD, Morel P. Results of surgical resection of liver metastases from non-colorectal primaries. Br J Surg 1998;85:1423–7CrossRefPubMed
2.
Benevento A, Boni L, Frediani L, Ferrari A, Dionigi R. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 2000;74:24–9CrossRefPubMed
3.
Karavias DD, Tepetes K, Karatzas T, Felekouras E, Androulakis J. Liver resection for metastatic non-colorectal non-neuroendocrine hepatic neoplasms. Eur J Surg Oncol 2002;28:135–9CrossRefPubMed
4.
Laurent C, Rullier E, Feyler A, Masson B, Saric J. Resection of noncolorectal and nonneuroendocrine liver metastases: late metastases are the only chance of cure. World J Surg 2001;25:1532–6PubMed
5.
Lindell G, Ohlsson B, Saarella A, Andersson R, Tranberg KG. Liver resection of noncolorectal secondaries. J Surg Oncol 1998;69:66–70CrossRefPubMed
6.
Maksan SM, Lehnert T, Bastert G, Herfarth C. Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 2000;26:209–12CrossRefPubMed
7.
Sakamoto Y, Ohyama S, Yamamoto J, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 2003;133:507–11CrossRefPubMed
8.
van Ruth S, Mutsaerts E, Zoetmulder FAN, van Coevorden F. Metastasectomy for liver metastases of non-colorectal primaries. Eur J Surg Oncol 2001;27:662–7CrossRefPubMed
9.
Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K. Resection of colorectal liver metastases: which prognostic factors should govern patient selection? Chirurg 2001;72:547–60CrossRefPubMed
10.
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66CrossRefPubMed
11.
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938–46PubMed
12.
Nordlinger B, Jaeck D, Guiguet M, Vaillant JC, Balladur P, Schaaal J. Surgical resection of hepatic metastases. In: Nordlinger B, Jaeck D, eds. Multicentric retrospective study by the French Association of Surgery. New York: Springer-Verlag, 1992:141–59
13.
Stangl R, Altendorf-Hofmann A, Charnley LM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405–10CrossRefPubMed
14.
Elias D, Cavalcanti de Albuqueque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998;187:487–93CrossRefPubMed
15.
Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997;121:625–32CrossRefPubMed
16.
Lang H, Nussbaum K-T, Weimann A, Raab R. Liver resection for non-colorectal, non-neuroendocrine hepatic metastases. Chirurg 1999;70:439–46CrossRefPubMed
17.
Zacherl M, Längle F, Steininger R, et al. Surgery for non-colorectal and non-neuroendocrine liver metastases. Wien Klin Wochenschr 2001;113:681–7PubMed
18.
Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In: DeVita VT Jr, Hellmann S, Rosenberg SA, eds. Cancer. Principals and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:1021–54
19.
Fumoleau P. Treatment of patients with liver metastases. Anticancer Drugs 1996;7(Suppl 2):21–3PubMed
20.
Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In: DeVita VT Jr, Hellmann S, Rosenberg SA, eds. Cancer. Principals and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:1054–87
21.
Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86–91CrossRefPubMed
22.
Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279–83CrossRefPubMed
23.
Seifert JK, Junginger T. Liver resections of metastases of non-colorectal primary tumors. Chirurg 1996;67:161–8PubMed
Metadata
Title
Changes in Indication and Results After Resection of Hepatic Metastases From Noncolorectal Primary Tumors: A Single-Institutional Review
Authors
Süleyman Yedibela, MD
Jonas Gohl, MD
Valentina Graz, MD
Mona Kathrin Pfaffenberger, MD
Susanne Merkel, MD
Werner Hohenberger, MD
and Thomas Meyer, PhD
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.11.018

Other articles of this Issue 10/2005

Annals of Surgical Oncology 10/2005 Go to the issue

OriginalPaper

TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up

Editorial

Hepatic Resection for Other Metastases

Educational Review

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions

OriginalPaper

Hydronephrosis Does Not Preclude Curative Resection of Pelvic Recurrences After Colorectal Surgery

OriginalPaper

Interleukin 8 in Human Hepatocellular Carcinoma Correlates With Cancer Cell Invasion of Vessels But Not With Tumor Angiogenesis

OriginalPaper

Prognostic Significance of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs Expression in Resected Pathologic Stage IIIA N2 Non–Small-Cell Lung Cancer